BMP Ref 3

Dhahbi, J.M. & Spindler, S.R. (2003) Aging of the Liver, In: Biology of Aging and its Modulation: Aging of the Organs and Systems, Aspinall, R. (Ed.), Kluwer Academic Publisher, The Netherlands. *In Press*.

J.M. DHAHBI¹ AND S.R. SPINDLER^{1, 2}

AGING OF THE LIVER

1. INTRODUCTION

Most organs are altered morphologically and functionally in old animals. To a varying extent, these age-related changes lead to a progressive loss of differentiated functions and physiologic capacities¹. For the liver, the data are inconsistent and conflicting regarding the effects of aging on structure and function². A number of reviews dealing with the physiology, structure and function of the aging liver have been published recently³⁻⁵. Reported morphological and structural changes do not generally correlate with the functional alterations found in the liver with age. These disparities raise the question of whether or not the observed changes with age actually compromise liver function, which led to the idea that the liver ages well when compared to other organs.

However, as described in a number of the reviews cited above, the liver does decline functionally with age. Our recent microarray studies of mice found that aging was accompanied by changes in gene expression linked to the development of the characteristic age-related liver pathologies⁶. These include hepatocellular carcinoma, fibrosis, cirrhosis, and unhealthful apolipoprotein and fatty acid biosynthesis. Aging increased gene expression associated with inflammation, cellular stress, and fibrosis, and reduced capacity for apoptosis, negative cell-growth control, and phase I and II xenobiotic metabolism. In this study, CR (calorie restriction) from weaning [long-term CR (LT-CR)], reversed the majority of these changes. Surprisingly, in very old mice just 2 to 4 weeks of CR [short-term CR (ST-CR)] reversed approximately 70% of these age-related changes in gene expression.

LT-CR and ST-CR also produced changes in the expression of genes which did not change with age. These *CR-specific* changes involved increased gluconeogenesis and disposal of the byproducts of extrahepatic protein catabolism, reduced glycolysis, and healthful changes in apolipoprotein and fatty acid biosynthesis. In addition, LT-CR and ST-CR produced changes in gene expression associated with enhance antiproliferative growth control, increased apoptosis and reduced chemical carcinogenesis. A number of other alterations in gene expression are associated with enhanced longevity in mice.

2. MICROARRAYS

Quantitative change in the activity of specific genes can control the rate of aging in invertebrates and mammals^{7,8}. Although there have been many studies of the relationship between aging, CR and hepatic gene expression, there are serious shortcomings in this literature. There are numerous cross-sectional studies of gene expression in animals of various ages which are interpreted as showing that the major effect of CR is to *prevent* age-related changes in gene expression (e.g. Ref 9). This interpretation has become pervasive in the literature, despite the cross-sectional nature of the studies. Funding and publication bias has reinforced this notion, producing a literature replete with reports of age-related changes in gene expression which appear to be *prevented* by CR.

Genome-wide DNA-microarrays are capable of quantifying the expression of all know genes in a single experiment. A significant strength of this approach is the absence of hypothesis-based bias in the choice of genes which are studied. Instead, a comprehensive profile of the relationship between a physiological state and gene expression is generated. Application of this technology has revealed the gene expression signatures underlying the physiological effects of aging, CR, and the dwarf mutations^{6,10-14}. In this way, microarrays are providing insights into aging, the development of age-related diseases, and the ameliorative actions of CR.

Our studies using this technology suggest that rather than simply preventing age-related changes in gene expression, CR instead acts rapidly to establish a new profile of gene expression which may better resist aging. Overall, ST-CR reproduced nearly 70% of the effects of LT-CR on genes that changed expression with age⁶. Thus, CR rapidly reversed, rather than prevented, many age-related changes in gene expression.

Another important effect of LT- and ST-CR was to establish the CR-specific patterns of gene expression. These CR-specific changes were in the same functional categories as the age-related changes. Further, CR in

young mice produced gene expression changes which were a subset of those produced in old CR mice. These similarities between CR in young and old mice, and between ST- and LT-CR led us to conclude that CR rapidly produces a new pattern of gene expression which better resists aging.

3. INTRA- AND INTERCELLULAR SIGNALING

Recently, a small family of single gene mutations which interfere with growth hormone (GH)/insulin-like growth factor-1 (IGF-1) signaling, resulting in dwarfism, have been shown to increase mean and maximal lifespans of mice by 40% to 70% beyond those of their heterozygous siblings^{8,15,16}. The dwarf mice are homozygous for loss-of-function mutations in the Pit1 (Snell dwarf mice), Prop1 (Ames dwarf mice), or GH receptor (GHR KO mice) loci. The Pit1 and Prop1 mutations prevent differentiation of the anterior pituitary, decreasing levels of thyroid hormone, growth hormone, IGF-1 and prolactin. The GHR KO is a more focused mutation, which prevents receptor mediated GH responsiveness. The mutations appear to slow the intrinsic rate of aging. Snell dwarf mice show delays in age-dependent collagen cross-linking and in six agesensitive indices of immune system status. These findings demonstrate that a single gene can control maximum lifespan and the timing of both cellular and extracellular senescence in mammals. The already enhanced lifespan of Ames dwarf mice can be further extended $\sim 25\%$ by CR¹⁷.

Our microarray studies found that the hepatic expression of IFG-I binding protein 1 decreased with age. This protein plays an important role in the negative regulation of the IGF-1 system, a stimulator of mitogenesis¹⁸. Given what is now known about the apparent role of IGF-1 signaling in aging, this change may have both pro-cancer and anti-aging effects.

CR repressed expression of GH receptor and iodothyronine deiodinase type I mRNA in the liver of both young and old mice, and induced overexpression of IGF binding protein mRNA, which inhibits IGF-1 signaling. Reduction in iodothyronine deiodinase type I expression should reduce hepatic conversion of the pro-hormone form of thyroid hormone (T_4) to the active form (T_3) . Down-regulation of this enzyme is likely responsible for the reduced levels of circulating T_3 found in CR rodents ¹⁹. Short-term treatment with low-calorie diets rapidly reduces circulating T_3 levels in morbidly obese men, apparently by reducing type I deiodinase activity ²⁰. Thus, CR appears to reduce thyroid hormone action in CR mice and humans.

Thus, some of the changes in gene expression induced by CR in mouse liver are associated with decreased GH receptor, IGF-1, and thyroid

hormone signaling. This is highly suggestive of the lifespan extending effects of the Prop-1 and Pit-1 mutations²¹. It suggests that the dwarf mutations and CR may work in part through the same signal transduction pathways.

4. AGE-RELATED INFLAMMATION

Published microarray studies of mammalian aging found that aging was associated with changes in gene expression linked to the development of the characteristic age-related pathologies of tissues such as liver, muscle and brain 6,13,22,23 . Our microarray studies of mouse liver revealed that aging was associated with other gene expression changes consistent with pathogenesis. We found age-associated induction in the expression of several genes important in inflammation including lysozyme and complement component 1, q, β^6 . Lysozyme is a myeloid cell-specific marker. Induction of this gene is normally associated with macrophage activation 24 . Complement component 1, q, β , a macrophage expressed protein, is a part of the recognition set of the complement C system, the primary humoral mediator of antigen-antibody reactions 25 . Activated macrophages, along with other inflammatory cells, are involved in a large number of liver diseases including cirrhosis, hepatitis, and sepsis- and endotoxin-induced liver injury 26 .

Old mice also overexpressed the mRNA for biglycan, a proteoglycan of the hepatic extracellular matrix, serum amyloid P-component, a glycoprotein present in all amyloid deposits, and cystatin B, an inhibitor of cysteine proteinases. In areas of inflammation, fibrogenic myofibroblasts express biglycan and other proteoglycans, lead to hepatic fibrosis²⁷. Serum amyloid P-component is one of the major acute phase reactants induced by inflammation in hepatocytes²⁸. Cystatins and their target enzymes play a role in many pathological events, including inflammatory disease²⁹. In the liver, an imbalance between cystatins and their targets can disregulate matrix degradation and accumulation, leading to hepatic fibrosis³⁰.

CR suppressed the age-associated increase in inflammatory and stress response genes. Consistent with decreased inflammatory response gene expression, CR delays the onset and diminishes the severity of autoimmune and inflammatory diseases in mice³¹. Decreased chaperone and stress response gene expression suggests that CR reduces the age-related physiological stress on the liver. Further, as discussed below, reduced chaperone expression is proapoptotic and anti-neoplastic. Thus, these effects may explain the delayed onset of hepatoma in CR mice³².

5. APOPTOSIS AND TUMORIGENESIS

Hepatocytes are mitotically competent, although they have long, mostly intermitotic lifespans. These lifespans appear to lead to the incremental accumulation of damage, and the gradual impairment of physiological functions. Thus, there is an important role for apoptosis in the maintenance of hepatic function. Apoptosis was initially viewed as potentially injurious to tissues, because it destroys cells. The current view recognizes that the role of apoptosis in aging is most likely tissue-specific. In every tissue, a balance must be struck between the need to maintain cell number and function, and the need to eliminate damaged, potentially toxic or neoplastic cells. This decision is crucial in largely postmitotic tissues such as brain. Brain apoptosis can contribute to neurological disorders of aging, including Alzheimer's disease. Parkinson's disease and stroke³³.

Hepatocytes are exposed to genotoxins from the diet and from free radicals generated by xenobiotic metabolism and beta-oxidation. These can produce elevated levels of DNA damage, a potential source of neoplasia. Apoptosis acts to eliminate the damaged and preneoplastic cells, which are then replaced by cell proliferation, thus maintaining homeostatic liver function.

The predominant morphologic change in aging human liver is termed brown atrophy³⁴. A brown color in aged liver cells results from the accumulation of lipofuscin in lysosomes. Liver atrophy results from an age-related decline in liver mass, resulting in fewer, larger hepatocytes. These observations suggest that aging is accompanied by a disregulation of apoptosis and cell division which fails to maintain youthful hepatocyte number and function during aging. Consistent with this idea, aging is associated with a decline in the rate of liver regeneration and apoptosis ^{35,36}. Likewise, aging is accompanied by an increase in liver tumors ^{37,38}.

6. AGING, CR AND HEPATIC CELL DIVISION

Our microarray studies found that 23% of the genes which decreased expression with age are involved in DNA replication and regulation of the cell cycle⁶. Most of these genes have a negative effect on cell growth and division. Thus, hepatic aging may be accompanied by a general loss of negative control of cell division. Among these genes, the product of phosphatase and tensin homolog gene is a tumor suppressor which induces cell-cycle arrest through inhibition of the phosphoinositide 3-kinase pathway³⁹. B-cell translocation gene 2 is a tumor suppressor which increases expression in response to DNA damage⁴⁰. The murine gene

product of the amino-terminal enhancer of split is a potent co-repressor of gene expression and cellular proliferation⁴¹. Calcium binding protein A11 binds to and regulates the activity of annexin II, which is involved in the transduction of calcium-related mitogenic signals⁴². As discussed above, IGF binding protein 1 negatively regulates the IGF-1 signaling¹⁸. Therefore, this change may be mitogenic.

Seventy-eight percent of the mice of this strain and sex fed the control diet used here die of some form of neoplasia, and the death rate from neoplasia accelerates dramatically with age³². Approximately 21% of these mice die of hepatoma, mostly late in life. Decreased expression of the negative growth regulators and overexpression of the chaperone genes with age are consistent with this higher incidence of hepatoma in aged mice.

LT- and ST-CR induced the expression of cyclin-dependent kinase 2-associated protein 1, a putative tumor suppressor gene⁴³. Overexpression of this gene suggests that LT- and ST-CR enhance anti-proliferative growth control. Consistent with this idea, IGF binding protein 7 gene expression was induced by LT-CR. The product of this gene functions both as an IGF binding protein and independently of IGF as a growth-suppressing factor⁴⁴. The expression of IGF binding protein 1, which has anti-growth activity through its inhibition of IGF-1 signaling, was reduced by age and restored by ST-CR. Thus, LT- and ST-CR may produce additional anti-proliferative effects on preneoplastic cells of the liver through their effects on the expression of these IGF binding protein family members.

7. AGING AND APOPTOSIS

Our microarray studies revealed that aging in mice was accompanied by elevated chaperone levels and the over expression of the other anti-apoptotic genes, myeloid cell leukemia sequence 1 and apoptosis inhibitory protein 6. These observations suggested that aging should be accompanied by a decrease in apoptotic potential of the liver. In contrast to this expectation, a number of studies reported that aging is accompanied by an increase in the intrinsic rate of apoptosis in rodent liver 45,35,46.

However, a recent study has clarified this conundrum. Suh et al. showed that the intrinsic rate of apoptosis in liver does increase slightly with age. But the increase was not significant in their study. However, they found a large and significant decrease in the apoptotic potential of the liver with age³⁶. Brief exposure to a direct-acting genotoxic alkylating agent produced high rates of apoptosis in the liver of young rats, but little apoptosis in the livers of old. These results suggest that the apoptotic capacity of the liver declines with age, while the basal rate of apoptosis may

increase slightly. These data suggest that damaged and preneoplastic cells likely accumulate with age in the liver. This interpretation is consistent with the increase in brown atrophy and hepatocellular neoplasms with age in mouse and man^{37,47}.

8. CR AND APOPTOSIS

Our genome-wide microarray studies found that 21% of the genes which changed expression in response to LT- and ST-CR are associated with apoptosis, cell growth, or cell survival⁶. LT-CR induced the expression of the Bcl2 homologous antagonist / killer and voltage-dependent anion channel 1 (porin) genes. Bcl2 homologous antagonist / killer is a proapoptotic member of the Bcl2 family of apoptosis regulators. It directly interacts with porin to release the pro-apoptotic factor cytochrome c from mitochondria, initiating apoptosis⁴⁸. The overexpression of porin found in ST-CR mice is consistent with the increase in apoptosis and reduction in chemical carcinogenesis found in fasting rodents^{49,50}. LT-CR decreased the expression of the anti-apoptotic genes interferon inducible ds RNA dependent inhibitor, X-box binding protein, and lymphocyte antigen 6 complex, locus E⁵¹⁻⁵³.

ST-CR reproduced the effects of LT-CR on the expression of 50% of the cell-cycle / DNA replication and apoptosis genes. The combination of these effects on gene expression suggests that ST-CR may be capable of rapidly reproducing the anti-neoplastic effects of LT-CR in very old animals. This conclusion is consistent with studies showing that short-term fasting increases apoptosis in preneoplastic lesions, and reduces rates of chemical carcinogenesis in the liver⁴⁹.

There is compelling evidence that CR increases the rate of apoptosis in preneoplastic and normal cells. The rate of apoptosis in the liver of mice, as measured using terminal dUTP nick end labeling (TUNEL) of apoptotic bodies, was 3 times higher in CR mice⁵⁴. Increased hepatocyte apoptosis was associated with a significantly lower incidence of spontaneous hepatomas throughout the lifespan of the CR mice. Using glutathione Stransferase-II (GST-II) as an immunohistochemical marker of preneoplastic liver cells, a progressive rise in GST-II labeling was seen with age in control mice³⁸. This increase was associated with a high incidence of GST-II positive liver tumors. GST-II expression was negligible in CR mice, which had a significant decrease in tumor incidence. One week of CR induced apoptosis in the GST-II-positive hepatocytes. In another study, CR eliminated 20-30% of liver cells by apoptosis, decreasing the number of preneoplastic liver foci by 85%⁵⁵. Apoptosis is significantly higher at all

ages in hepatocytes from CR mice³⁵. CR enhances apoptosis in other organs as well, including gastrointestinal tract, bladder, spleen and lymph nodes⁵⁶⁻⁵⁸.

9. CHAPERONES, AGING, AND CR

A consistent finding of our genome-wide microarray and conventional studies was that the mRNA and protein levels of essentially every endoplasmic-reticulum chaperone increased with age and decreased with CR in the liver^{6,59-61}. Similar results were obtained in several other tissues. The induction of chaperone gene expression in the livers of aged mice may be a physiological adaptation to increased oxidative or possibly other stress during aging. For a number of years the meaning of these changes was unclear. In the past few years, the relationship between chaperones and health is beginning to be understood.

Stress-inducible chaperones respond to a diverse group of stimuli including heat, oxidative and ischemic stress, inflammation, hemodynamics, and exposure to toxic chemicals⁶²⁻⁶⁴. Under such conditions, these inducible chaperones associate with abnormally folded proteins to promote their renaturation, prevent their aggregation, or promote their degradation if they cannot be properly refolded. A number of years ago, Richardson and his colleagues found that the heat inducibility of the stress-responsive chaperone, hsp70 was significantly reduced in hepatocytes isolated from old rats⁶⁵. Similar results were found in fibroblasts from donors of various ages⁶⁶. Richardson and colleagues also found that in old rats maintained on LT-CR, there was no decrease in the response of hsp70 to hyperthermia⁶⁵.

However, inducible chaperones like hsp70 cannot be detected in the absence of physiological stress. They play a different role than the chaperones which are present continuously in cells in the absence of physiological stress, which is by far the most common physiological state. Most proteins require interactions with constitutively expressed molecular chaperones for their biosynthesis, maturation, processing, intracellular transport, and secretion⁶⁷. Chaperones also perform cytoprotective functions, including prevention of protein denaturation and aggregation, the repair of structurally damaged proteins⁶⁸, and promotion of the ubiquination and proteasomal degradation of malfolded, damaged proteins^{69,70}. In this context, it might appear that constitutive overexpression of chaperones would be healthful, perhaps by preventing the accumulation of lipofuscin. However, another function of chaperones appears to mitigate this possible benefit.

Chaperone levels are a part of molecular decision making following genotoxic stress. Elevated chaperone levels tip the balance away from apoptosis and toward cell survival^{71,72}. As described above, aging increases chaperone expression and decreases the apoptotic response to genotoxic stress³⁶. The increase in chaperone expression with age may explain why hepatocellular neoplasms are the most common lesions in older mice^{37,47}. In contrast, CR, which reduces endoplasmic reticulum chaperone levels in the liver and other tissues, enhances apoptosis⁷²⁻⁷⁶. Enhanced apoptosis by CR may account for its well-documented anti-cancer benefits⁷⁷.

The linkage between chaperone levels and apoptosis also extends to fasting and feeding. While feeding increases chaperone levels, fasting reduces the levels of nearly every endoplasmic reticulum and cytoplasmic chaperone we investigated 61,78. Fasting also increases apoptosis of preneoplastic lesions and reduces the rate of chemical carcinogenesis 49,50. This connection between caloric intake and chaperone levels may link food intake to the capacity for protein folding, assembly, and processing within cells. The level of chaperone expression in response to feeding does not depend on endoplasmic reticulum protein trafficking 78. It appears to be regulated by the blood insulin-to-glucagon ratio.

10. MOLECULAR MECHANISMS LINKING CHAPERONES, PROTEIN SECRETION AND CARCINOGENESIS

Chaperone induction has emerged as a new anti-apoptotic mechanism^{79,80}. Elevated chaperone levels during tumorigenesis allow cells to survive carcinogenesis and tumor formation⁸¹. Induced GRP78, GRP94 and GRP170 are essential for the survival, growth and immuno-resistance of transformed cells⁸²⁻⁸⁴. Tumorigenesis-associated chaperone induction confers drug resistance to the tumors^{74,85-89}. Chaperone induction allows precancer cells to survive the DNA damage and mutations which result in transformation, proliferation and onset of carcinogenesis^{73-76,90}.

Chaperone induction might reduce the production or secretion of apoptogenic signals, or increase the production or secretion of apoptosis inhibitory proteins. Several studies indicate that the abundance of endoplasmic reticulum chaperones influences the secretion efficiency of many liver proteins ⁹¹⁻⁹³. The interaction between chaperones and other proteins can enhance either protein folding, maturation and processing, or enhance the degradation of proteins ^{94,95}. It appears that the longer a protein spends in association with chaperones, the greater the chance it will undergo degradation ⁹⁵⁻⁹⁸. We found that CR, which decreased the level of most endoplasmic reticulum chaperones, increased the rate, efficiency and

level of hepatic protein secretion⁶¹. It is thus possible, that the effect of CR on endoplasmic reticulum chaperone levels and secretion efficiency may change the activity of receptor mediated apoptotic pathways. It may change the display or secretion of pro- or anti-apoptotic receptors or ligands.

The increase in secretory protein output in response to CR may also enhance the turnover of serum proteins. This may decrease circulating levels of glycated serum proteins, which are associated with micro- and macrovascular damage, nephropathy, neuropathy, retinopathy and atherosclerotic disease^{99,100}. Modified plasma proteins appear to be significant contributors to the development of age- and diabetes-related renal, vascular, ocular and neurological pathologies, and to aging itself¹⁰¹⁻¹⁰³. CR reduces the age-related accumulation of glycoxidation products in blood and tissue proteins¹⁰⁴⁻¹⁰⁶.

11. XENOBIOTIC METABOLISM

The effect of aging on hepatic drug metabolism is extremely important due to its effects on both carcinogenesis and its practical implications in determining the drug doses that are safe for older individuals. A decline in hepatic drug metabolism and clearance, and an increase in adverse drug reactions are common hallmarks of human and rodent aging. The liver's capacity to metabolize xenobiotics declines with age⁴. Pharmacokinetic evidence in humans indicates that aging is accompanied by reduced liver phase I drug metabolism. For example, cytochrome P450 content in human subjects decreases 30% after 70 years of age¹⁰⁷. Altered drug metabolism has been attributed to a decline in liver volume and blood flow in humans, although these changes may only partly account for the decline in the metabolism and clearance of drugs with aging in man¹⁰⁷. In rodent studies, there is compelling evidence for a decline in phase I and phase II enzyme activities and expression, although the specific enzymes which are altered may vary with strain and species^{6,108-110}.

In our microarray and conventional studies, aging decreased expression of xenobiotic metabolism genes⁶. This is an additional class of proneoplastic changes in gene expression encountered in our microarray studies. The genes for the phase I enzymes amine N-sulfotransferase and three cytochrome P450 isozymes, as well as the gene for the phase II enzyme glutathione S-transferase-like gene were negatively regulated by age. Decreased expression of Phase I enzyme genes in the liver of aged rodents has been reported in many studies 108,111,112. Decreased expression of such genes is likely responsible in part for the age-related decline in the xenobiotic metabolizing capacity of the liver. This decline is a recognized

source of adverse drug reactions in aged mammals². It may contribute to the increase in neoplasms with age in mice.

LT- and ST-CR reversed the age-related decrease in the expression of genes such as the B-cell translocation gene 2, amino-terminal enhancer of split, glutathione-S-transferase like, amine N-sulfotransferase, and cytochrome P450, 2f2 mRNAs. This CR effect is consistent with the delayed onset of hepatoma in CR mice. Partial restoration of the hepatic drug metabolizing and detoxifying functions of the liver may be a source of the anti-aging and anti-cancer effects of CR. These results suggest that ST-CR may rapidly restore some differentiated functions in tissues of older animals.

12. INTERMEDIARY METABOLISM

Energy metabolism in the liver is altered by aging. For example, at least two studies have shown decreased mitochondrial respiratory rates in the liver with age^{113,114}. Perhaps the major effects of age are on homeostatic glucose regulation. The liver plays a critical role in maintaining glucose homeostasis. This homeostasis is controlled by hormones such as insulin, glucagon, growth hormone, and IGF-1. High levels of glucose and insulin are implicated in many age-associated pathologies¹¹⁵. Likewise, loss of homeostatic glucose regulation is a hallmark of mammalian aging¹¹⁶. CR reduces blood glucose and insulin concentrations in rodents, primates and humans¹¹⁷⁻¹¹⁹. Disorders associated with elevated glucose levels are reduced or mitigated entirely by CR. These facts indicate that the antiaging effects of CR may be mediated by alteration of the normal sequence of age-related metabolic changes in the liver.




Figure. 1. Summary of the effects of age and CR on the glycolytic and gluconeogenic pathways of the liver. Glycolytic metabolism in the liver involves three irreversible. regulated steps. Glucokinase (GK) initiates glucose metabolism by phosphorylation of C6 yielding glucose 6-phosphate (G6P). The committed step in glycolysis, and the second irreversible and regulated step, is the phosphorylation of Fru 6-P by phosphofructokinase (PFK-1) to produce fructose 1,6-bisphosphate (Fru 1,6-P₂). The third irreversible step controls the outflow of the pathway. Phosphoenolpyruvate (PEP) and ADP are utilized by pyruvate kinase (PK) to produce pyruvate (PYR) and ATP. Pyruvate dehydrogenase (PDH) oxidatively decarboxylates pyruvate to form acetyl-CoA, which is a bridge between glycolysis and the tricarboxylic acid cycle. Phosphoenolpyruvate carboxykinase (PEPCK) catalyzes the first committed step in gluconeogenesis. The main non-carbohydrate precursors for gluconeogenesis are amino acids from the diet, and from muscle protein breakdown. Other organs also contribute amino acids, but muscle is the major source. Most of these amino acids are converted to oxaloacetate (OA), which is metabolized to PEP by PEPCK. In the second regulated and essentially irreversible step in gluconeogenesis, fructose 1,6-bisphosphatase (Fru 1,6-P₂ase) catalyzes the formation of fructose 6-phosphate (Fru 6-P) from fructose 1,6bisphosphate (Fru 1,6-P₂). Finally, in the third essentially irreversible reaction of gluconeogenesis, glucose is formed by the hydrolysis of G6P in a reaction catalyzed by glucose 6-phosphatase (G6Pase). Substrates are not boxed, enzyme names are in shaded boxes, summaries of experimental results are in double bordered boxes, and amino acids are indicated by "AA" in triple bordered boxes. When two values are given following "CR", they represent the fold change in the young and old mice, respectively. The value after "Age" is the main effect of age. A down arrow indicates the percent decrease, an up arrow indicates the fold increase. The value given for age is a combination of both dietary groups. NC is no change

13. AGING AND HEPATIC ENERGY METABOLISM

In general terms, our studies of the effects of aging on key hepatic and muscle enzymes of glucose homeostasis indicated that aging is accompanied by a decline in the enzymatic capacity for the turnover and utilization of peripheral protein for the production of glucose by the liver (Figs. 1 and 2). We found an age-related decrease in the expression of phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6pase) mRNA in the liver of mice (Fig. 1)^{120,121}. An age-related decrease in PEPCK mRNA also was reported in hepatocytes isolated from rats of various ages¹²². This enzyme catalyzes the committing step in gluconeogenesis, the conversion of oxaloacetate to phosphoenolpyruvate (Fig. 1). Once carbon is converted to phosphoenolpyruvate it will be converted to glucose in the liver. PEPCK controls the flow of carbon for hepatic glucose production. This carbon is derived from amino acid intermediates (principally glutamine) derived from the turnover of protein in the periphery for energy generation. There are no known allosteric modifiers of the activity of any PEPCK isoform¹²³. PEPCK mRNA and activity are excellent indicators of the enzymatic capacity for gluconeogenesis in the liver. Thus, aging appears to reduce the gluconeogenic capacity of the liver (Fig. 1).

Liver gluconeogenesis derives its substrates mainly from protein turnover in the peripheral tissues, suggesting that aging is accompanied by a decrease in the turnover of peripheral protein. During the postabsorptive state, muscle and other tissues utilize amino acids derived from protein turnover to generate energy via the TCA cycle. This amino acid catabolism is initiated in the muscle by two enzymatic steps, collectively called the transdeamination reaction (Fig. 2). Transdeamination leads to the liberation of the amino nitrogen as ammonia. Because of its extreme toxicity, this ammonia is transferred to glutamate by glutamine synthetase, producing glutamine. Glutamine serves to transfer both carbon and nitrogen to the liver. Aging leads to a decrease in the activity of muscle glutamine synthetase. This is consistent with an age-related decrease in the turnover of peripheral protein for energy production. It is also consistent with decreased expression of hepatic carbamylphosphate synthase-1, glutamine synthetase, and tyrosine aminotransferase (TAT; Fig. 2).

Glutamine produced in the muscle is metabolized in the liver by glutaminase into glutamate and ammonia. The ammonia derived from this reaction can be returned to the glutamine pool by liver glutamine synthetase

(Fig. 2). An age-related decrease in glutamine synthetase activity would channel glutamine into gluconeogenesis. The nitrogen from this glutamine would be channeled by carbamylphosphate synthase-1 into the urea cycle for detoxification and disposal. These effects are likely responsible for a part of the decrease in muscle protein synthesis and turnover known to occur with age¹²⁴.




Figure 2. Summary of the effects of age and diet on muscle and liver nitrogen metabolism. In muscle and other extrahepatic tissues, the degradation of proteins to amino acids is utilized for generating metabolic energy. Transdeamination of amino acids produces tricarboxylic acid cycle intermediates and ammonia. Glutamine synthetase synthesizes glutamine from glutamate and ammonia. Glutamine is transported to the liver where glutaminase releases the ammonia, regenerating glutamate. CPSI converts this ammonia to carbamyl phosphate, which is converted to urea in the urea cycle. The amino group of excess tyrosine is released by TAT as ammonia, which is also detoxified beginning with the action of cpsI. In the figure, substrates are not boxed, enzyme names are in shaded boxes, and summaries of experimental results are in double bordered boxes. When two values are given following "CR", they represent the fold change in the young and old mice, respectively. The value after "Age" is the main effect of age. A down arrow indicates the percent decrease, an up arrow indicates the fold increase. The value given for age is a combination of both dietary groups. NC is no change.

14. CR AND HEPATIC ENERGY METABOLISM

In our microarray studies, CR modified the expression of a significant number of genes coding for key metabolic enzymes 6 . ST-CR increased expression of glutamate oxaloacetate transaminase 1 and decreased expression of pyruvate dehydrogenase $E1\alpha$ subunit. These changes are consistent with our conventional molecular-biological and biochemical studies showing that CR increases shuttling of nitrogen and carbon to the

liver from the peripheral tissues. It increases the enzymatic capacity of the liver for gluconeogenesis and the disposal of the byproducts of extrahepatic protein catabolism for energy production, while reducing the enzymatic capacity for glycolysis ^{121,125}. These CR effects are consistent with theories of aging, such as the oxidative stress theory, which postulate that the accumulation of damaged proteins contributes to the rate of aging ¹²⁶.

CR increased fasting levels of the mRNA and activity of PEPCK and mRNA of G6pase¹²¹. The abundance of PEPCK mRNA was greater in the liver of young and old CR mice than it was in control mice of the same ages. PEPCK activity also was higher in the liver of CR mice. As discussed above, aging decreased the mRNA for PEPCK and G6Pase. In addition, when CR and control mice were fasted overnight and fed their normal daily ration of food, PEPCK mRNA and activity decreased within 1.5 hours of feeding in both control and CR mice. However, its mRNA abundance and activity increased rapidly thereafter, especially in CR mice. By 5 hours after feeding, PEPCK activity in CR mice was approximately twice that of controls. Similarly, G6Pase mRNA abundance was higher in CR mice for the 5 hours following feeding. G6Pase catalyzes the terminal step in hepatic glucose production, the hydrolysis of glucose 6-phosphate to glucose and inorganic phosphate (Fig. 1). This step leads to the release of glucose from the liver into the circulation when blood glucose levels would otherwise fall.

Together, these results suggest that the enzymatic capacity for gluconeogenesis returns rapidly after feeding. Thus, higher levels of peripheral tissue turnover persist in CR mice, even after feeding. These mice are at approximate weight equilibrium 127. Therefore, in CR mice feeding is accompanied by intensified protein biosynthetic activity followed immediately by peripheral protein turnover. CR mice are approximately 4 times more insulin sensitive than control mice 120.

Consistent with the interpretation offered above, CR and age decreased the expression of glutamine synthetase activity and mRNA in the liver, while age decreased and CR increased its expression in muscle (Fig. 2). These differential effects should lead to a transfer of carbon and nitrogen in the form of glutamine from the periphery to the liver, where it would increase the hepatic pool of glutamine. The increase in glutaminase expression would increase hepatic catabolism of glutamine, producing glutamate and ammonia. mRNA levels closely reflect the levels of glutaminase activity ^{128,129}. Ammonia production by glutaminase is closely coupled to urea synthesis by CPSI. CPSI mRNA levels in young and old CR mice were twice that of control mice ^{121,125}. CR leads to coordinate

induction of carbamylphosphate synthase-1 transcription, mRNA, protein, and activity¹³⁰. The resulting glutamate accumulation would fuel CR enhanced gluconeogenesis.

These data support the interpretation that CR leads to enhanced carbon flux from amino acid degradation in the peripheral tissues to the liver. This amino acid degradation extends to tyrosine, an amino acid that requires a liver specific enzyme, TAT, for catabolism¹²¹. TAT degradation of tyrosine is well known to provide ketogenic and gluconeogenic substrates to the liver when glucose is limiting and amino acids are utilized as a major source of energy. Aging decreased TAT mRNA in the liver by an average of 37%. TAT mRNA in CR mice was approximately double the level in control mice. The age-related changes in nitrogen metabolizing enzymes are consistent with a decrease in catabolism of extrahepatic protein for energy. CR appears to enhance the capacity for mobilizing and transporting carbon and nitrogen products of muscle protein catabolism to the liver. CR mice also have enhanced hepatic capacity for the biosynthesis of glucose from this carbon, and for the detoxification of this nitrogen.

15. CONCLUSIONS

While the physiological and structural studies of the liver suggest that it ages well, the molecular biology and biochemistry of the liver indicate that it undergoes changes with age that have serious systemic effects. Genomewide microarray and conventional molecular and biochemical studies indicate that there is an age-related shift in liver toward a state associated with oncogenesis, fibrosis, cirrhosis, and unhealthful apolipoprotein and fatty acid biosynthesis. Evidence was found for age-related increases in inflammation, cellular stress, and fibrosis; and for reduced capacity for apoptosis, negative cell-growth control, and phase I and II xenobiotic metabolism. LT- and ST-CR reversed the majority of these changes. LT-CR also produced CR-specific changes in signal transduction-associated gene expression known to lead to enhanced longevity. Evidence for a CRrelated increase in the turnover and renewal of peripheral protein also was found. In addition, healthful changes in apolipoprotein and fatty acid biosynthesis-related gene expression were found. LT- and ST-CR produced changes in gene expression associated with enhanced anti-proliferative growth control, increased apoptosis and reduced chemical carcinogenesis. Together these studies make it clear that aging and its mitigation by CR are multifaceted processes which affect many aspects of liver function at the molecular level. It also appears that unbiased, exploratory approaches such as the genome-wide microarray studies described here are providing new and valuable insights into these processes.

16. REFERENCES

- 1. Dice JF (1993) Cellular and molecular mechanisms of aging. Physiol Rev 73: 149-159
- 2. Schmucker DL (1998) Aging and the liver: An update. J Gerontol : Biol Sci 53A: B315-B320 $\,$
- 3. Joh T, Itoh M, Katsumi K, Yokoyama Y, Takeuchi T, Kato T, Wada Y, Tanaka R (1986) Physiological concentrations of human epidermal growth factor in biological fluids: use of a sensitive enzyme immunoassay. Clin Chim Acta 158: 81-90
- 4. Durnas C, Loi CM, Cusack BJ (1990) Hepatic drug metabolism and aging. Clin Pharmacokinet 19: 359-389
- 5. Sotaniemi EA, Arranto AJ, Pelkonen O, Pasanen M (1997) Age and cytochrome P45-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther 61: 331-339
- Cao SX, Dhahbi JM, Mote PL, Spindler SR (2001) Genomic profiling of short- and long-term caloric restriction in the liver of aging mice. Proc Natl Acad Sci U S A 98: 10630-10635
- 7. Guarente L, Kenyon C (2000) Genetic pathways that regulate ageing in model organisms [In Process Citation]. Nature 408: 255-262
- 8. Brown-Borg HM, Borg KE, Meliska CJ, Bartke A (1996) Dwarf mice and the ageing process [letter]. Nature 384: 33
- 9. Ward W, Richardson A (1991) Effect of age on liver protein synthesis and degradation. Hepatology 14: 935-948
- 10. Kaminski N, Allard JD, Pittet JF, Zuo F, Griffiths MJ, Morris D, Huang X, Sheppard D, Heller RA (2000) Global analysis of gene expression in pulmonary fibrosis reveals distinct programs regulating lung inflammation and fibrosis. Proc Natl Acad Sci U S A 97: 1778-1783
- 11. Welsh JB, Zarrinkar PP, Sapinoso LM, Kern SG, Behling CA, Monk BJ, Lockhart DJ, Burger RA, Hampton GM (2001) Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci U S A 98: 1176-1181
- 12. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES (1999) Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286: 531-537
- 13. Lee CK, Weindruch R, Prolla TA (2000) Gene-expression profile of the ageing brain in mice. Nat Genet 25: 294-297
- 14. Kayo T, Allison DB, Weindruch R, Prolla TA (2001) Influences of aging and caloric restriction on the transcriptional profile of skeletal muscle from rhesus monkeys. Proc Natl Acad Sci U S A 98: 5093-5098
- 15. Coschigano KT, Clemmons D, Bellush LL, Kopchick JJ (2000) Assessment of growth parameters and life span of GHR/BP gene-disrupted mice. Endocrinology 141: 2608-2613
- 16. Flurkey K, Papaconstantinou J, Miller RA, Harrison DE (2001) Lifespan extension and delayed immune and collagen aging in mutant mice with defects in growth hormone production. Proc Natl Acad Sci U S A 98: 6736-6741
- 17. Bartke A, Wright JC, Mattison JA, Ingram DK, Miller RA, Roth GS (2001) Extending the lifespan of long-lived mice. Nature 414: 412
- 18. Frystyk J, Delhanty PJ, Skjaerbaek C, Baxter RC (1999) Changes in the circulating IGF system during short-term fasting and refeeding in rats. Am J Physiol 277: E245-E252

- 19. Herlihy JT, Stacy C, Bertrand HA (1990) Long-term food restriction depresses serum thyroid hormone concentrations in the rat. Mech Ageing Dev 53: 9-16
- 20. Katzeff HL, Yang M-U, Presta E, Leibel RL, Hirsch J, Van Itallie TB (1990) Calorie restriction and iopanoic acid effects on thyroid hormone metabolism. Am J Clin Nutr 52: 263-266
- 21. Kealy RD, Lawler DE, Ballam JM, Mantz SL, Biery DN, Greeley EH, Lust G, Segre M, Smith GK, Stowe HD (2002) Effects of diet restriction on life span and age-related changes in dogs. J Am Vet Med Assoc 220: 1315-1320
- 22. Jiang CH, Tsien JZ, Schultz PG, Hu Y (2001) The effects of aging on gene expression in the hypothalamus and cortex of mice. Proc Natl Acad Sci U S A 98: 1930-1934
- 23. Lee CK, Klopp RG, Weindruch R, Prolla TA (1999) Gene expression profile of aging and its retardation by caloric restriction. Science 285: 1390-1393
- 24. Keshav S, Chung P, Milon G, Gordon S (1991) Lysozyme is an inducible marker of macrophage activation in murine tissues as demonstrated by in situ hybridization. J Exp Med 174: 1049-1058
- 25. Petry F, Reid KB, Loos M (1989) Molecular cloning and characterization of the complementary DNA coding for the B-chain of murine Clq. FEBS Lett 258: 89-93
- 26. Jaeschke H (1997) Cellular adhesion molecules: regulation and functional significance in the pathogenesis of liver diseases. Am J Physiol 273: G602-G611
- 27. Friedman SL (1993) Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med 328: 1828-1835
- 28. Pepys MB, Baltz M, Gomer K, Davies AJ, Doenhoff M (1979) Serum amyloid P-component is an acute-phase reactant in the mouse. Nature 278: 259-261
- 29. Buttle DJ, Abrahamson M, Burnett D, Mort JS, Barrett AJ, Dando PM, Hill SL (1991) Human sputum cathepsin B degrades proteoglycan, is inhibited by alpha 2- macroglobulin and is modulated by neutrophil elastase cleavage of cathepsin B precursor and cystatin C. Biochem J 276 (Pt 2): 325-331
- 30. Kos J, Lah TT (1998) Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer (review). Oncol Rep 5: 1349-1361
- 31. Cherry, Engelman RW, Wang BY, Kinjoh K, El Badri NS, Good RA (1998) Calorie restriction delays the crescentic glomerulonephritis of SCG/Kj mice. Proc Soc Exp Biol Med 218: 218-222
- 32. Weindruch R, Walford RL, Fligiel S, Guthrie D (1986) The retardation of aging in mice by dietary restriction: longevity, cancer, immunity and lifetime energy intake. J Nutr 116: 641-654
- 33. Warner HR (1997) Aging and regulation of apoptosis. Curr Top Cell Regul 35: 107-121
- 34. Pieri C, ZS-Nagy I, Mazzufferi G, Giuli C (1975) The aging of rat liver as revealed by electron microscopic morphometry-- I. Basic parameters. Exp Gerontol 10: 291-304
- 35. Muskhelishvili L, Hart RW, Turturro A, James SJ (1995) Age-related changes in the intrinsic rate of apoptosis in livers of diet-restricted and ad libitum-fed B6C3F1 mice. Am J Pathol 147: 20-24
- 36. Suh Y, Lee KA, Kim WH, Han BG, Vijg J, Park SC (2002) Aging alters the apoptotic response to genotoxic stress. Nat Med 8: 3-4
- 37. Weindruch R, Walford RL (1982) Dietary restriction in mice beginning at 1 year of age: effect on life- span and spontaneous cancer incidence. Science 215: 1415-1418
- 38. Muskhelishvili L, Turturro A, Hart RW, James SJ (1996) Pi-class glutathione-S-transferase-positive hepatocytes in aging B6C3F1 mice undergo apoptosis induced by dietary restriction. Am J Pathol 149: 1585-1591
- 39. Cantley LC, Neel BG (1999) New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A 96: 4240-4245

- 40. Cortes U, Moyret-Lalle C, Falette N, Duriez C, Ghissassi FE, Barnas C, Morel AP, Hainaut P, Magaud JP, Puisieux A (2000) BTG gene expression in the p53-dependent and -independent cellular response to DNA damage. Mol Carcinog 27: 57-64
- 41. Pinto M, Lobe CG (1996) Products of the grg (Groucho-related gene) family can dimerize through the amino-terminal Q domain. J Biol Chem 271: 33026-33031
- 42. Puisieux A, Ji J, Ozturk M (1996) Annexin II up-regulates cellular levels of p11 protein by a post- translational mechanisms. Biochem J 313 (Pt 1): 51-55
- 43. Todd R, McBride J, Tsuji T, Donoff RB, Nagai M, Chou MY, Chiang T, Wong DT (1995) Deleted in oral cancer-1 (doc-1), a novel oral tumor suppressor gene. FASEB J 9: 1362-1370
- 44. Oh Y, Nagalla SR, Yamanaka Y, Kim HS, Wilson E, Rosenfeld RG (1996) Synthesis and characterization of insulin-like growth factor-binding protein (IGFBP)-7. Recombinant human mac25 protein specifically binds IGF-I and -II. J Biol Chem 271: 30322-30325
- 45. Higami Y, Shimokawa I, Okimoto T, Tomita M, Yuo T, Ikeda T (1997) Effect of aging and dietary restriction on hepatocyte proliferation and death in male F344 rats. Cell Tissue Res 288: 69-77
- 46. Ando K, Higami Y, Tsuchiya T, Kanematsu T, Shimokawa I (2002) Impact of aging and life-long calorie restriction on expression of apoptosis-related genes in male F344 rat liver. Microsc Res Tech 59: 293-300
- 47. Muskhelishvili L, Hart RW, Turturro A, James SJ (1995) Age-related changes in the intrinsic rate of apoptosis in livers of diet-restricted and ad libitum-fed B6C3F1 mice. Am J Pathol 147: 20-24
- 48. Shimizu S, Tsujimoto Y (2000) Proapoptotic BH3-only Bcl-2 family members induce cytochrome c release, but not mitochondrial membrane potential loss, and do not directly modulate voltage-dependent anion channel activity. Proc Natl Acad Sci U S A 97: 577-582
- 49. Pitot HC, Hikita H, Dragan Y, Sargent L, Haas M (2000) Review article: the stages of gastrointestinal carcinogenesis--application of rodent models to human disease. Aliment Pharmacol Ther 14 Suppl 1:153-60: 153-160
- 50. Hikita H, Vaughan J, Babcock K, Pitot HC (1999) Short-term fasting and the reversal of the stage of promotion in rat hepatocarcinogenesis: role of cell replication, apoptosis, and gene expression. Toxicol Sci 52: 17-23
- 51. Tang NM, Korth MJ, Gale M, Wambach M, Der SD, Bandyopadhyay SK, Williams BR, Katze MG (1999) Inhibition of double-stranded RNA- and tumor necrosis factor alphamediated apoptosis by tetratricopeptide repeat protein and cochaperone P58(IPK). Mol Cell Biol 19: 4757-4765
- 52. Reimold AM, Etkin A, Clauss I, Perkins A, Friend DS, Zhang J, Horton HF, Scott A, Orkin SH, Byrne MC, Grusby MJ, Glimcher LH (2000) An essential role in liver development for transcription factor XBP-1. Genes Dev 14: 152-157
- 53. Treister A, Sagi-Assif O, Meer M, Smorodinsky NI, Anavi R, Golan I, Meshel T, Kahana O, Eshel R, Katz BZ, Shevach E, Witz IP (1998) Expression of Ly-6, a marker for highly malignant murine tumor cells, is regulated by growth conditions and stress. Int J Cancer 77: 306-313
- 54. James SJ, Muskhelishvili L (1994) Rates of apoptosis and proliferation vary with caloric intake and may influence incidence of spontaneous hepatoma in C57BL/6 x C3H F1 mice. Cancer Res 54:5508-5510
- 55. Grasl-Kraupp B, Bursch W, Ruttkay-Nedecky B, Wagner A, Lauer B, Schulte-Hermann R (1994) Food restriction eliminates preneoplastic cells through apoptosis and antagonizes carcinogenesis in rat liver. Proc Natl Acad Sci U S A 91: 9995-9999
- 56. Holt PR, Moss SF, Heydari AR, Richardson A (1998) Diet restriction increases apoptosis in the gut of aging rats. J Gerontol: Biol Sci 53A: B168-B172

- 57. Dunn SE, Kari FW, French J, Leininger JR, Travlos G, Wilson R, Barrett JC (1997) Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res 57: 4667-4672
- 58. Luan X, Zhao W, Chandrasekar B, Fernandes G (1995) Calorie restriction modulates lymphocyte subset phenotype and increases apoptosis in MRL/lpr mice. Immunol Lett 47: 181-186
- 59. Spindler SR, Crew MD, Mote PL, Grizzle JM, Walford RL (1990) Dietary energy restriction in mice reduces hepatic expression of glucose-regulated protein 78 (BiP) and 94 mRNA. J Nutr 120: 1412-1417
- 60. Dhahbi JM, Mote PL, Tillman JB, Walford RL, Spindler SR (1997) Dietary energy tissue-specifically regulates endoplasmic reticulum chaperone gene expression in the liver of mice. J Nutr 127: 1758-1764
- 61. Dhahbi JM, Cao SX, Tillman JB, Mote PL, Madore M, Walford RL, Spindler SR (2001) Chaperone-mediated regulation of hepatic protein secretion by caloric restriction. Biochem Biophys Res Commun 284: 335-339
- 62. Marber MS, Mestril R, Chi SH, Sayen MR, Yellon DM, Dillmann WH (1995) Overexpression of the rat inducible 70-kD heat stress protein in a transgenic mouse increases the resistance of the heart to ischemic injury. J Clin Invest 95: 1446-1456
- 63. Kyriakis JM, Avruch J (1996) Sounding the alarm: protein kinase cascades activated by stress and inflammation. J Biol Chem 271: 24313-24316
- 64. Jacquier-Sarlin MR, Fuller K, Dinh-Xuan AT, Richard MJ, Polla BS (1994) Protective effects of hsp70 in inflammation. Experientia 50: 1031-1038
- 65. Heydari AR, Wu B, Takahashi R, Strong R, Richardson A (1993) Expression of heat shock protein 70 is altered by age and diet at the level of transcription. Mol Cell Biol 13: 2909-2918 66. Gutsmann-Conrad A, Heydari AR, You SH, Richardson A (1998) The expression of heat
- shock protein 70 decreases with cellular senescence in vitro and in cells derived from young and old human subjects. Exp Cell Res 241: 404-413
- 67. Wickner S, Maurizi MR, Gottesman S (1999) Posttranslational quality control: folding, refolding, and degrading proteins. Science 286: 1888-1893
- 68. Hartl FU (1996) Molecular chaperones in cellular protein folding. Nature 381: 571-579
- 69. Medina R, Wing SS, Goldberg AL (1995) Increase in levels of polyubiquitin and proteasome mRNA in skeletal muscle during starvation and denervation atrophy. Biochem J 307 (Pt 3): 631-637
- 70. Sherman MY, Goldberg AL (1996) Involvement of molecular chaperones in intracellular protein breakdown. EXS 77: 57-78
- 71. Ciocca DR, Fuqua SA, Lock-Lim S, Toft DO, Welch WJ, McGuire WL (1992) Response of human breast cancer cells to heat shock and chemotherapeutic drugs. Cancer Res 52: 3648-3654
- 72. McMillan DR, Xiao X, Shao L, Graves K, Benjamin IJ (1998) Targeted disruption of heat shock transcription factor 1 abolishes thermotolerance and protection against heat-inducible apoptosis. J Biol Chem 273: 7523-7528
- 73. McCormick TS, McColl KS, Distelhorst CW (1997) Mouse lymphoma cells destined to undergo apoptosis in response to thapsigargin treatment fail to generate a calcium-mediated grp78/grp94 stress response. J Biol Chem 272: 6087-6092
- 74. Jamora C, Dennert G, Lee AS (1996) Inhibition of tumor progression by suppression of stress protein GRP78/BiP induction in fibrosarcoma B/C10ME. Proc Natl Acad Sci U S A 93: 7690-7694
- 75. Migliorati G, Nicoletti I, Crocicchio F, Pagliacci C, D'Adamio F, Riccardi C (1992) Heat shock induces apoptosis in mouse thymocytes and protects them from glucocorticoid-induced cell death. Cell Immunol 143: 348-356

- 76. Wei YQ, Zhao X, Kariya Y, Fukata H, Teshigawara K, Uchida A (1994) Induction of apoptosis by quercetin: involvement of heat shock protein. Cancer Res 54: 4952-4957
- 77. Schulte-Hermann R, Bursch W, Grasl-Kraupp B, Mullauer L, Ruttkay-Nedecky B (1995) Apoptosis and multistage carcinogenesis in rat liver. Mutat Res 333: 81-87
- 78. Dhahbi JM, Cao SX, Mote PL, Rowley BC, Wingo JE, Spindler SR (2002) Postprandial induction of chaperone gene expression is rapid in mice. J Nutr 132: 31-37
- 79. Rao RV, Peel A, Logvinova A, del Rio G, Hermel E, Yokota T, Goldsmith PC, Ellerby LM, Ellerby HM, Bredesen DE (2002) Coupling endoplasmic reticulum stress to the cell death program: role of the ER chaperone GRP78. FEBS Lett 514: 122-128
- 80. Rao RV, Hermel E, Castro-Obregon S, del Rio G, Ellerby LM, Ellerby HM, Bredesen DE (2001) Coupling endoplasmic reticulum stress to the cell death program. Mechanism of caspase activation. J Biol Chem 276: 33869-33874
- 81. Koong AC, Chen EY, Lee AS, Brown JM, Giaccia AJ (1994) Increased cytotoxicity of chronic hypoxic cells by molecular inhibition of GRP78 induction. Int J Radiat Oncol Biol Phys 28: 661-666
- 82. Cai JW, Henderson BW, Shen JW, Subjeck JR (1993) Induction of glucose regulated proteins during growth of a murine tumor. J Cell Physiol 154: 229-237
- 83. Patierno SR, Tuscano JM, Kim KS, Landolph JR, Lee AS (1987) Increased expression of the glucose-regulated gene encoding the Mr 78,000 glucose-regulated protein in chemically and radiation-transformed C3H 10T1/2 mouse embryo cells. Cancer Res 47: 6220-6224
- 84. Menoret A, Meflah K, Le Pendu J (1994) Expression of the 100-kda glucose-regulated protein (GRP100/endoplasmin) is associated with tumorigenicity in a model of rat colon adenocarcinoma. Int J Cancer 56: 400-405
- 85. Chatterjee S, Cheng MF, Berger SJ, Berger NA (1994) Induction of M(r) 78,000 glucose-regulated stress protein in poly(adenosine diphosphate-ribose) polymerase- and nicotinamide adenine dinucleotide-deficient V79 cell lines and its relation to resistance to the topoisomerase II inhibitor etoposide. Cancer Res 54: 4405-4411
- 86. Chatterjee S, Cheng MF, Berger RB, Berger SJ, Berger NA (1995) Effect of inhibitors of poly(ADP-ribose) polymerase on the induction of GRP78 and subsequent development of resistance to etoposide. Cancer Res 55: 868-873
- 87. .Shen J, Hughes C, Chao C, Cai J, Bartels C, Gessner T, Subjeck J (1987) Coinduction of glucose-regulated proteins and doxorubicin resistance in Chinese hamster cells. Proc Natl Acad Sci U S A 84: 3278-3282
- 88. Sugawara S, Nowicki M, Xie S, Song HJ, Dennert G (1990) Effects of stress on lysability of tumor targets by cytotoxic T cells and tumor necrosis factor [published erratum appears in J Immunol 1991 Feb 1;146(3):1083]. J Immunol 145: 1991-1998
- 89. Sugawara S, Takeda K, Lee A, Dennert G (1993) Suppression of stress protein GRP78 induction in tumor B/C10ME eliminates resistance to cell mediated cytotoxicity. Cancer Res 53: 6001-6005
- 90. Johnson RJ, Liu N, Shanmugaratnam J, Fine RE (1998) Increased calreticulin stability in differentiated NG-108-15 cells correlates with resistance to apoptosis induced by antisense treatment. Brain Res Mol Brain Res 53: 104-111
- 91. Knittler MR, Haas IG (1992) Interaction of BiP with newly synthesized immunoglobulin light chain molecules: cycles of sequential binding and release. EMBO J 11: 1573-1581
- 92. Dorner AJ, Krane MG, Kaufman RJ (1988) Reduction of endogenous GRP78 levels improves secretion of a heterologous protein in CHO cells. Mol Cell Biol 8: 4063-4070
- 93. Dorner AJ, Wasley LC, Kaufman RJ (1992) Overexpression of GRP78 mitigates stress induction of glucose regulated proteins and blocks secretion of selective proteins in Chinese hamster ovary cells. EMBO J 11: 1563-1571

- 94. Beggah A, Mathews P, Beguin P, Geering K (1996) Degradation and endoplasmic reticulum retention of unassembled alpha- and beta-subunits of Na,K-ATPase correlate with interaction of BiP. J Biol Chem 271: 20895-20902
- 95. Sato R, Imanaka T, Takatsuki A, Takano T (1990) Degradation of newly synthesized apolipoprotein B-100 in a pre- Golgi compartment. J Biol Chem 265: 11880-11884
- 96. Bonifacino JS, Lippincott-Schwartz J (1991) Degradation of proteins within the endoplasmic reticulum. Curr Opin Cell Biol 3: 592-600
- 97. Amara JF, Lederkremer G, Lodish HF (1989) Intracellular degradation of unassembled asialoglycoprotein receptor subunits: a pre-Golgi, nonlysosomal endoproteolytic cleavage. J Cell Biol 109: 3315-3324
- 98. Lippincott-Schwartz J, Bonifacino JS, Yuan LC, Klausner RD (1988) Degradation from the endoplasmic reticulum: disposing of newly synthesized proteins. Cell 54: 209-220
- 99. Vlassara H (1997) Recent progress in advanced glycation end products and diabetic complications. Diabetes 46 Suppl 2: S19-S25
- 100. Yan SD, Stern D, Schmidt AM (1997) What's the RAGE? The receptor for advanced glycation end products (RAGE) and the dark side of glucose. Eur J Clin Invest 27: 179-181
- 101. Masoro EJ, Katz MS, McMahan CA (1989) Evidence for the glycation hypothesis of aging from the food- restricted rodent model. J Gerontol 44: B20-B22
- 102. Vlassara H, Bucala R (1996) Recent progress in advanced glycation and diabetic vascular disease: role of advanced glycation end product receptors. Diabetes 45 Suppl 3: S65-S66
- 103. Beisswenger PJ, Makita Z, Curphey TJ, Moore LL, Jean S, Brinck-Johnsen T, Bucala R, Vlassara H (1995) Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes 44: 824-829
- 104. Cefalu WT, Bell-Farrow AD, Wang ZQ, Sonntag WE, Fu MX, Baynes JW, Thorpe SR (1995) Caloric restriction decreases age-dependent accumulation of the glycoxidation products, N epsilon-(carboxymethyl)lysine and pentosidine, in rat skin collagen. J Gerontol A Biol Sci Med Sci 50: B337-B341
- 105. Dyer DG, Dunn JA, Thorpe SR, Lyons TJ, McCance DR, Baynes JW (1992) Accumulation of Maillard reaction products in skin collagen in diabetes and aging. Ann NY Acad Sci 663: 421-422
- 106. Sell DR, Lane MA, Johnson WA, Masoro EJ, Mock OB, Reiser KM, Fogarty JF, Cutler RG, Ingram DK, Roth GS, Monnier VM (1996) Longevity and the genetic determination of collagen glycoxidation kinetics in mammalian senescence. Proc Natl Acad Sci U S A 93: 485-490
- 107. Thompson PD, Hsieh JC, Whitfield GK, Haussler CA, Jurutka PW, Galligan MA, Tillman JB, Spindler SR, Haussler MR (1999) Vitamin D receptor displays DNA binding and transactivation as a heterodimer with the retinoid X receptor, but not with the thyroid hormone receptor. J Cell Biochem 75: 462-480
- 108. Mote PL, Grizzle JM, Walford RL, Spindler SR (1990) Age-related down regulation of hepatic cytochrome P1-450, P3-450, catalase and CuZn-superoxide dismutase RNA. Mech Ageing Dev 53: 101-110
- 109. Sun JQ, Lau PP, Strobel HW (1986) Aging modifies the expression of hepatic microsomal cytochromes P-450 after pretreatment of rats with beta-naphthoflavone or phenobarbital. Exp Gerontol 21: 65-73
- 110. Richardson A, Rutherford MS, Birchenall-Sparks MC, Robert MS, Wu WT, Cheung HT (1985) Levels of specific messenger RNA species as a function of age. In Sohal RS, Birnbaum LS, Cutler RG (eds) Molecular biology of aging: Gene stability and gene expression, pp. 229-241. Raven Press, New York

- 111. Ali B, Walford RL, Imamura T (1985) Influence of aging and poly IC treatment on xenobiotic metabolism in mice. Life Sci 37: 1387-1393
- 112. Mote PL, Grizzle JM, Walford RL, Spindler SR (1991) Influence of age and caloric restriction on expression of hepatic genes for xenobiotic and oxygen metabolizing enzymes in the mouse. J Gerontol 46: B95-B100
- 113. Yen TC, Chen YS, King KL, Yeh SH, Wei YH (1989) Liver mitochondrial respiratory functions decline with age. Biochem Biophys Res Commun 165: 944-1003
- 114. Muller-Hocker J, Aust D, Rohrbach H, Napiwotzky J, Reith A, Link TA, Seibel P, Holzel D, Kadenbach B (1997) Defects of the respiratory chain in the normal human liver and in cirrhosis during aging. Hepatology 26: 709-719
- 115. Rossetti L, Giaccari A, DeFronzo RA (1990) Glucose toxicity. Diabetes Care 13: 610-630 116. Halter JB (1995) Carbohydrate metabolism. In Masoro EJ (ed) Handbook of physiology. Section 11: Aging, pp. 119-145. Oxford University Press, New York, NY
- 117. Lane MÅ, Ball SS, Ingram DK, Cutler RG, Engel J, Read V, Roth GS (1995) Diet restriction in rhesus monkeys lowers fasting and glucose- stimulated glucoregulatory end points. Am J Physiol 268: E941-E948
- 118. Harris SB, Gunion MW, Rosenthal MJ, Walford RL (1994) Serum glucose, glucose tolerance, corticosterone and free fatty acids during aging in energy restricted mice. Mech Ageing Dev 73: 209-221
- 119. Walford RL, Harris SB, Gunion MW (1992) The calorically restricted low-fat nutrient-dense diet in Biosphere 2 significantly lowers blood glucose, total leukocyte count, cholesterol, and blood pressure in humans. Proc Natl Acad Sci U S A 89: 11533-11537
- 120. Spindler SR (2001) Caloric restriction enhances the expression of key metabolic enzymes associated with protein renewal during aging. Annals of the New York Academy of Sciences 928: 296-304
- 121. Dhahbi JM, Mote PL, Wingo J, Tillman JB, Walford RL, Spindler SR (1999) Calories and aging alter gene expression for gluconeogenic, glycolytic, and nitrogen-metabolizing enzymes. Am J Physiol 277: E352-E360
- 122. Wimonwatwatee T, Heydari AR, Wu WT, Richardson A (1994) Effect of age on the expression of phosphoenolpyruvate carboxykinase in rat liver. Am J Physiol 267: G201-G204
- 123. Hanson RW, Reshef L (1997) Regulation of phosphoenolpyruvate carboxykinase (GTP) gene. Annu Rev Biochem 66: 581-611
- 124. Van Remmen H, Ward WF, Sabia RV, Richardson A (1995) Gene expression and protein degradation. In Masoro EJ (ed) Handbook of Physiology. Section 11: Aging, pp. 171-234. Oxford University Press, New York, NY
- 125. Dhahbi JM, Mote PL, Wingo J, Rowley BC, Cao SX, Walford R, Spindler SR (2001) Caloric restriction alters the feeding response of key metabolic enzyme genes. Mech Ageing Dev 122: 35-50
- 126. Stadtman ER, Berlett BS (1998) Reactive oxygen-mediated protein oxidation in aging and disease. Drug Metab Rev 30: 225-243
- 127. Weindruch R, Klopp RG, Mote PL, Allison DB, Pugh TD, Spindler S R (2002) Life-Span and Diseases of Mice Fed Popular Dietary Supplements from Middle Age. J Gerontol In Press
- 128. Watford M, Vincent N, Zhan Z, Fannelli J, Kowalski T, Kovacevic Z (1994) Transcriptional control of rat hepatic glutaminase expression by dietary protein level and starvation. J Nutr 124: 493-499
- 129. Zhan Z, Vincent NC, Watford M (1994) Transcriptional regulation of the hepatic glutaminase gene in the streptozotocin-diabetic rat. Int J Biochem 26: 263-268
- 130. Tillman JB, Dhahbi JM, Mote PL, Walford RL, Spindler SR (1996) Dietary calorie restriction in mice induces carbamyl phosphate synthetase I gene transcription tissue specifically. J Biol Chem 271: 3500-3506

17. ABBREVIATIONS

CR, caloric restriction; G6pase, glucose-6-phosphatase; GH, growth hormone; GST-II, glutathione S-transferase-II; IGF-1; insulin-like growth factor-1; LT-CR, long-term CR; PEPCK, phosphoenolpyruvate carboxykinase; ST-CR, short-term CR.

18. AFFILIATIONS

¹BioMarker Pharmaceuticals Inc., Campbell, California 95008 ²Department of Biochemistry, University of California, Riverside, Riverside, California 92521